09:50 AM EST - Helix BioPharma Corp. : announced that it has filed an investigational new drug application with the United States Food and Drug Administration seeking approval to perform its planned Phase I clinical safety and tolerability study of its cancer drug candidate L-DOS47. Helix BioPharma Corp.
shares T.HBP are trading up $0.13 at $2.70.
